Endocrinological Outcome of Endoscopic Transsphenoidal Surgery for Functioning and Non-Functioning Pituitary Adenoma

Lee Shwu Yi1,2, Azmi Alias1, Abdul Rahman Izaini Ghani2, Mohammad Badrulnizam Long Bidin3

1 Department of Neurosurgery, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
2 Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia
3 Department of Endocrinology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

Submitted: 2 Jan 2019
Accepted: 3 Apr 2019
Online: 28 Jun 2019

Abstract

Introduction: The present study analysed the (i) remission and preservation of hormones, (ii) endocrinological and anatomical complications and (iii) visual improvement after endoscopic transsphenoidal surgery (ETS).

Methods: The retrospective observational study of all consecutive cases of pituitary adenoma treated with ETS in Hospital Kuala Lumpur (HKL) between 2006 and 2015. Age, sex, pre- and post-operative hormone level, tumour size, and complications were noted.

Results: A total of 67 patients were diagnosed with non-functioning pituitary adenoma throughout this period. Of these, 11 patients had both visual and hormonal improvement post-operation. Of the 27 patients with tumour invaded into the cavernous sinus, 13 showed an improved vision. In the adenoma patients who had impaired hormonal function before the surgery, the hormone level normalised post-surgery in 42 patients.

Moreover, 39 patients were diagnosed with functioning pituitary adenoma. Ten patients recovered from acromegaly and four patients recovered from Cushing disease within seven days post-operative. Also, five patients with functioning adenoma suffered complications.

Conclusion: Outcome for the preservation and hormone recovery in non-functioning pituitary adenoma group was satisfactory, with only one patient's hormonal level worsening. No visual deterioration and mortality were detected throughout this study. A dedicated team specialised in endoscopic transsphenoidal pituitary surgery further improved the outcome of this surgical method.

Keywords: endoscopy, pituitary adenoma, transsphenoidal surgery

Introduction

Surgical approaches to the pituitary region have undergone numerous refinements over the last 100 years. Diseases of the pituitary gland demand a holistic and multidisciplinary approach.

Surgery is a well-established first-line treatment for a host of pituitary lesions. Surgical decompression of the pituitary gland and its stalk may lead to the recovery of hypopituitarism caused by all forms of adenoma in up to 60% of the patients. The primary goal of surgery in pituitary lesions is the maximal removal of the tumour while preserving the gland function (1).
The common post-surgery complications include cerebrospinal fluid (CSF) leakage (4.7%), meningitis (2%), and visual deterioration (2%) (2–8). The rate of post-operative hypopituitarism in other transsphenoidal tumour resections series is commonly < 20%.

Methods

Patient Population and Initial Evaluation

The present retrospective observational study consisted of all consecutive cases of pituitary adenoma treated with endoscopic transsphenoidal surgery (ETS) in Hospital Kuala Lumpur (HKL) between 2006 and 2015. This study was approved by the Research and Ethics committee KKM (NMRR ID: 32233).

All patients diagnosed with functional and non-functional pituitary adenoma treated with ETS were included in this study. Moreover, patients with pituitary adenoma treated with transcranial and microscopic approach and patients treated with endoscopic transsphenoidal procedure but the histopathological examination (HPE) did not report any pituitary adenoma, were excluded.

All ETSs were performed by a single consultant neurosurgeon and otorhinolaryngological (ORL) surgeon at HKL, using the standard endoscopic surgical technique described in the literature (two surgeons/four hands).

Patients were managed through a multidisciplinary approach together with neurosurgeon, endocrinologist, neuroradiologist, and ORL surgeon. Pre-operative assessment included hormonal profile and pre-operative optimisation by the endocrinologist and the anesthetist. The radiographic evaluation consisted of a magnetic resonance imaging (MRI) scan, with and without contrast, performed pre-operatively and repeated every 3–6 months during the first year and subsequently every year. The medical records were reviewed to evaluate pre- and post-operative hormonal status, pathology reports, MRI characteristics, operative notes, and clinic follow-up notes from the patient’s neurosurgeon and endocrinologist. All patients were required to have a minimum of three months of post-operative follow-up.

Hormonal Range

All patients underwent a baseline pre-operative pituitary panel and post-operative hormonal evaluation (minimum three months post-surgical follow-up) in a retrospective manner to determine the overall impact on the pituitary gland function. The normal range of hormones was set based on the local lab results.

Before the operation, all patients underwent a hormonal and clinical assessment by an endocrinologist.

The biochemical remission of acromegaly is defined as a decrease in growth hormone (GH) < 5.0 ng/mL of functioning pituitary adenomas within 12 days post-operatively (9).

Moreover, the remission of Cushing’s disease is defined as the morning (AM) cortisol level < 137 nmol/L within seven days post-operation (10). For HKL, the current practice is to measure the AM cortisol level on post-operative day 1. If the AM cortisol level is high, the test is repeated on days 3, 7, 14, and 28.

Imaging Characteristics

The pre-operative and post-operative MRI and CT brain reports were reviewed. The formula ABC/2 was used, where A = maximum tumour diameter, B = diameter of the tumour perpendicular to A, and C = maximum height of the tumours as reported on the MRI scan. The degree of resection was calculated by measuring the residual tumour volume in the post-operative scan, which was corroborated by reviewing the surgeons’ operation report (11).

Visual Assessment

The Humphrey’s chart is used by a dedicated neuro-ophthalmologist to interpret the visual field and assess the visual acuity pre-operatively, post-operatively, at 3–6 months for the first year, and yearly thereafter.

Complications

The complications, such as rhinological features, CSF leaks, infection, and vascular complications (bleeding), were classified according to the anatomical structures involved in the operative stages (12, 13).

Statistical Analysis

Descriptive analysis was performed using SPSS version 20. Chi-square test was used to study the association between the study groups with respect to the gender and age of
the participants, while Fisher’s exact test was used to study the association between the study groups and improvement in the vision field. A combination of chi-square test and Fisher’s exact test was used to study the correlation between the study groups and their complications.

The pre- and post-operative endocrine outcomes were tabulated in Microsoft Excel. Mc Nemar test was used to evaluate the pre- and post-operative endocrine outcomes for non-functioning pituitary adenoma patients.

**Results**

**Descriptive Analysis**

In this study, a total of 106 patients, diagnosed with pituitary adenoma and underwent transphenoidal surgery, were included from 2006 until 2015. Of these, 67 patients were diagnosed with non-functioning pituitary adenoma, and 39 were diagnosed with functioning pituitary adenoma. The non-functioning pituitary group consisted of 58.2% (n = 39) males and 41.8% (n = 28) females, while the functioning pituitary group consisted of 51.3% (n = 20) males and 48.7% (n = 19) females. Thus, the majority of the participants in both groups were males. However, no significant association was detected between the study groups and gender (P = 0.489).

Nonetheless, a significant difference was noted in the age in both groups (P < 0.05). About 26.9% (n = 18) of non-functioning pituitary adenoma patients were 50–59 years-old, while 33.3% (n = 13) of the functioning pituitary adenoma patients were < 30 years-old (Table 1).

**Improvement in vision field (non-functioning pituitary adenoma) post-operation and preservation of hormones**

In the non-functioning pituitary adenoma group, vision and hormones improved in 16.40% (n = 11) patients, while 83.60% (n = 56) did not report any changes within three months post-operation (Table 2).

**Improvement in vision field (non-functioning pituitary adenoma) post-operation and invasion to cavernous sinus**

In the group of patients with tumour that has invaded into the cavernous sinus, vision was improved in 10.45% (n = 7) patients, while 29.85% (n = 20) did not exhibit any changes (Table 3).

| Table 1. Demography for functioning and non-functioning pituitary adenoma patient |
|---------------------------------|---------------------------------|---------------------------------|
| **Non-functioning pituitary adenoma** | **Functioning pituitary adenoma** |
| Male 39 (58.2) | 20 (51.3) |
| Female 28 (41.8) | 19 (48.7) |
| Age (years) | | |
| < 30 7 (10.4) | 13 (33.3) |
| 30–39 12 (17.9) | 8 (20.5) |
| 40–49 16 (23.9) | 5 (12.8) |
| 50–59 18 (26.9) | 10 (25.6) |
| > 60 14 (20.9) | 3 (7.7) |

*Chi-square test is used

| Table 2. Improvement in vision field in non-functioning pituitary adenoma post-operation and preservation of hormone |
|---------------------------------|
| **Non-functioning pituitary adenoma** | **Improved** | **Deteriorated** | **No Changes** |
| 16.40% (11) | 0 | 83.60% (56) |

* Fisher’s exact test
Table 3. Improvement in vision field (non-functioning pituitary adenoma) post-operation and invasion to cavernous sinus

| Non-functioning | Invasion to Cavernous Sinus |
|-----------------|-----------------------------|
|                 | Yes | No |
| Visual Outcome  |     |    |
| Improved        | 10.45% (7) | 5.97% (4) |
| Deteriorated    | 0 | 0 |
| No changes      | 29.85% (20) | 53.73% (36) |

\[ P = 0.10 \]

*Fisher’s exact test

Pre-/post-operative endocrine outcomes for pituitary adenoma patients

In non-functioning pituitary adenoma group, 24 (35.81%) patients presented normal endocrine function pre-operatively. Of these, 5 (7.46%) patients experienced impaired endocrine function post-operatively, while that in the remaining 19 (28.35%) remained normal.

Moreover, of the 43 (64.18%) patients with impaired hormonal levels pre-operatively, 42 (62.69%) recovered within three months post-operatively. Only one (1.49%) patient exhibited poor condition plausibly due to the invasion to the cavernous sinus.

The functioning group consisted of 32 acromegaly patients and seven Cushing disease patients. Of these, 10 (31.25%) patients recovered from acromegaly within 12 weeks after the operation and four (57.14%) recovered from Cushing disease in the same time frame (Table 4).

Pre-/post-operative endocrine outcomes for non-functioning pituitary adenoma patients

Hormones level were improved post-operatively. Also, statistically significant differences were detected between pre- and post-operation (Table 5).

Hormones that improve after ETS

All the hormones were normalised after decompression surgery. This phenomenon was apparent for cortisol, thyroxine, TSH, and prolactin (Table 6).

Complications

This study showed that there were more complications for functioning pituitary adenoma with 5.1% (n = 2) of the patients suffering post-operative bleeding, CSF leak 5.1% (n = 2), and rhinological problem 2.6% (n = 1) as compared to non-functioning pituitary adenoma, wherein only 4.5% (n = 3) of the patients suffered post-operative complications due to CSF leak (Table 7).

Hence, patients with functioning pituitary adenoma required more medical attention as compared to the non-functioning pituitary adenoma patients.

No mortality occurred within 30 days post-operation.

Table 4. Pre-/post-operative endocrine outcomes for pituitary adenoma patients

| Tumour subtype     | Normal/Normal | Impaired/Recovered | Impaired/Impaired | Impaired/Worse | Normal/Impaired | Grand total |
|--------------------|---------------|--------------------|------------------|---------------|----------------|-------------|
| Functioning        | -             | 14 (35.89%)        | 25 (64.10%)      | -             | -              | 39 (100%)   |
| Acromegaly         | -             | 10 (31.25%)        | 22 (68.75%)      | -             | -              | 32 (100%)   |
| Cushing disease    | -             | 4 (57.14%)         | 3 (42.85%)       | -             | -              | 7 (100%)    |
| Non-functioning    | 19 (28.35%)   | 42 (62.69%)        | -                | 1 (1.49%)     | 5 (7.46%)      | 67 (100%)   |
| Grand total        | 19 (17.92%)   | 56 (52.83%)        | 25 (23.58%)      | 1 (0.94%)     | 5 (4.72%)      | 106 (100%)  |
Table 5. Pre-/post-operative endocrine outcomes for non-functioning pituitary adenoma patients

| Hormone pre-op/ Hormone post-op | Normal | Abnormal | Total |
|----------------------------------|--------|----------|-------|
| Normal                           | 19     | 5        | 24    |
| Abnormal                         | 42     | 1        | 43    |
| Total                            | 61     | 6        | 67    |

*Mc Nemar test

Table 6. Hormones that improved after ETS

| Condition       | Improved | Normal |
|-----------------|----------|--------|
| Cortisol level  | 8        | 57     |
| Thyroxine level | 8        | 57     |
| TSH level       | 8        | 57     |
| ACTH level      | 2        | 1      |
| GH level        | 7        | 36     |
| PRL level       | 8        | 53     |
| LH level        | 7        | 49     |
| FSH level       | 7        | 50     |
| Testestrone level | 4       | 23     |
| Estradiol level | 3        | 10     |

Table 7. Complications post-endoscopic transsphenoidal excision of pituitary adenoma

| Complication          | Yes/No | Study group                  | P     |
|-----------------------|--------|------------------------------|-------|
|                       |        | Non-functioning pituitary adenoma | Functioning pituitary adenoma |       |
|                       |        | 67 (100.0)                  | 37 (94.9) | 0.061* |
|                       |        | 0 (0.0)                     | 2 (5.1)  |       |
| Bleeding              |        | 64 (95.5)                   | 37 (94.9) | 0.879* |
|                       |        | 3 (4.5)                     | 2 (5.1)  |       |
| CSF leak              |        | 67 (100.0)                  | 39 (100.0) | n/a   |
|                       |        | 0 (0.0)                     | 1 (2.6)  |       |
| Meningitis            |        | 67 (100.0)                  | 38 (97.4) | 0.188* |
|                       |        | 0 (0.0)                     | 1 (2.6)  |       |
| Rhinological          |        | 67 (100.0)                  | 38 (97.4) | 0.188* |
|                       |        | 0 (0.0)                     | 0 (0.0)  |       |
| Visual deterioration  |        | 67 (100.0)                  | 38 (97.4) | 0.188* |
|                       |        | 0 (0.0)                     | 0 (0.0)  |       |

*Fisher’s exact test
Discussion

The development of endoscopic pituitary surgery represents the natural extension of endoscopic nasosinusal procedures. The potential benefits of the endoscopic technique include improved visualisation. With the use of wide-angle endoscopes 0°, 30°, 45°, and 70°, the operating surgeon has a much wider field of view and illumination as compared to that using a microscope.

This study focused on patients treated with ETS conducted by a single neurosurgeon in a 10-year-duration in order to analyse the remission and preservation of hormones, the endocrinological and anatomical complications, and the visual improvement in the same cohort treated with ETS.

The comparison of the present study with that of Karppinen (14) revealed a similar female and male ratio and age group; however, compared to the study by Marić et al. (11) in 2011, Marić et al.’s study consist of more females than males, and the functioning pituitary group was larger than the non-functioning group.

Furthermore, analysing the pre-operative position of the normal gland is a major step of the planning and surgery techniques, especially if the goal is to maintain the function of the pituitary gland. For many patients, maintaining the normal gland has higher priority as compared to the resection of the tumour (8).

Herein, of the 24 (35.81%) patients with normal endocrine function pre-operatively, 5 (7.46%) lost the function post-operatively. On the other hand, of the 43 (64.18%) patients with impairment pre-operatively, 42 (62.69%) recovered post-operatively. Only 1 (1.49%) patient’s hormone level declined post-ETS, which could be attributed to the extended invasion into the cavernous sinus. This phenomenon is improved when compared to 7.3% in Edward et al. (2).

However, 7.46% with a normal function pre-operatively, lost their function post-operatively; this was higher when compared to the 3.6% in Edward et al. (2). Among the patients who had lost the hormone function, prolactin level was altered in 3 out of 5 patients.

The functioning group consisted of 32 acromegaly patients and seven Cushing disease patients. Of these, 10 (31.25%) patients recovered from acromegaly and 4 (57.14%) recovered from Cushing disease. Thus, it could be deduced that all the hormones improved after decompression surgery (8, 15, 16, 17).

After ETS, vision improved mainly due to the decompression over the optic chiasma (18). Only 16.40% (n = 11) of the non-functioning pituitary adenoma patients in this study had improved or preserved vision and hormone function. None of the patients exhibited any deterioration in the hormones. Another factor that would determine the vision improvement is tumour invasion to the cavernous sinus. The vision was improved in 10.45% of the patients post-surgery while 29.85% did not present any improvement.

The complication of CSF leak in the non-functioning pituitary adenoma was 4.5% (n = 3). In the functioning pituitary adenoma, 5.1% (n = 2) patients showed CSF leak and epistaxis while rhinological problems occurred 2.6% (n = 1). When compared to the study by Abtin et al. (19), which was based on multiple large cohorts, the reported mortality rate for traditional surgery was < 1%. The 1%–4% reported incidences for both epistaxis and CSF leak were almost similar to the results obtained from the present study (8).

This small difference in the outcome of surgery might be attributed to patient factor (bleeding during operation) and tumour factors (invasion to cavernous sinus and tumour encasing the internal carotid artery) (7). In this study, the surgeon was not a factor as only one surgeon performed all the surgeries.

Limitations

The data obtained were descriptive and from a single institution. In addition to the small number of patients, statistical analysis could not be performed between certain groups as this was a descriptive analysis study.

Conclusions

Hormonal preservation and recovery are crucial for assessing the outcome of the surgery and the quality of life of the patient. With the advancement of endoscopy, MRI, and other modern technologies, the operation outcome has significantly improved with fewer post-operative complications.

In the current study, the outcome for the preservation and hormone recovery in the non-functioning pituitary adenoma group was...
satisfactory, with only one (1.49%) patient’s hormone worsening. Any visual deterioration and mortality were not observed throughout the study.

The present study was made possible due to well-coordinated teamwork between the neurosurgeon, endocrinologist, neuroradiologist, otorhinolaryngologist, neuropathologist, and neuroanatomist.

**Recommendations**

The outcome of ETS can be improved by having:

i. a dedicated team specialised in this type of surgery.

ii. major focus placed on the functioning group as the acromegaly and Cushing disease remission rate is low.

iii. an aggressive approach to achieve higher remission rate.

iv. benchmarking and adopting best practices from other institutions.

**Acknowledgements**

This work was carried out at the Departments of Neurosurgery, Hospital Kuala Lumpur. I thank the many people who have helped and supported me during this study.

I am especially grateful to Mr Azmi Alias for performing the surgery and being my mentor both in the operating room and in this manuscript, Datuk Dr Mohammad Badrulnizam Long Bidin for his kindness to share his patients’ data and opinions.

**Ethics of Study**

This study was approved by the Research and Ethics committee KKM (NMRR ID: 32233).

**Conflict of Interest**

None.

**Funds**

None.

**Authors’ Contributions**

Conception and design: AA, LSY
Analysis and interpretation of the data: LSY
Drafting of the article: LSY
Critical revision of the article for important intellectual content: AA, MBLB, ARIG
Final approval of the article: AA
Provision of study materials or patients: MBLB

**Correspondence**

Dr Lee Shwu Yi
MD (Lomonosov Moscow State University)
Department of Neurosurgery,
Hospital Kuala Lumpur,
53000 Jalan Pahang,
Kuala Lumpur.
Tel: +6017 3236301
Fax: +603 26989845
E-mail: predencelee@hotmail.com

**References**

1. Cappabianca P, Cavallo LM, de Divitiis O, Solari D, Esposito F, Colao A. Endoscopic pituitary surgery. *Pituitary*. 2008;11(4):385–390. https://doi.org/10.1007/s11102-008-0087-5

2. Edward RL, Sherry LI, David JC, Whitney W, Liangge H, Charles HC. A benchmark for preservation of normal pituitary function after endoscopic transsphenoidal surgery for pituitary macroadenomas. *World Neurosurg.* 2016;91:371–375. https://doi.org/10.1016/j.wneu.2016.04.059

3. Farrell CJ, Nyquist GG, Farag AA, Rosen MR, Evans JJ. 2016. Principles of pituitary surgery. *Otolaryngol Clin North Am.* 2016;49(1):95–106. https://doi.org/10.1016/j.otc.2015.09.005

4. Gondim JA, de Almeida JP, Albuquerque LAF, Schops M, Gomes E, Ferraz T, et al. Endoscopic endonasal approach for pituitary adenoma: surgical complications in 301 patients. *Pituitary*. 2011;14(2):174–183 https://doi.org/10.1007/s11102-010-0280-1

5. Gondim JA, Schops M, de Almeida JP, Albuquerque LAF, Gomes E, Ferraz T. Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. *Pituitary*. 2010;13(1):68–77. https://doi.org/10.1007/s11102-009-0195-x
6. Magro E, Graillon T, Lassave J, Castinetti F, Boissonneau S, Tabouret E, et al. Complications related to endoscopic endonasal transsphenoidal approach for non-functioning pituitary macroadenomas in 300 consecutive patients. World Neurosurg. 2016;89:442–453. https://doi.org/10.1016/j.wneu.2016.02.059

7. Paluzzi A, Fernandez-Miranda JC, Stefkos T, Chailinor S, Snyderman CH, Gardner PA. Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. Pituitary. 2014;17(4):307–319. https://doi.org/10.1007/s11102-013-0502-4

8. Swearingen B. Update on pituitary surgery. J Clin Endocrinol Metab. 2012;97(4):1073–1081. https://doi.org/10.1210/jc.2011-3237.

9. Katznelson L, Laws ER, Melmed S, Molitch ME, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700

10. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–2831. https://doi.org/10.1210/jc.2015-1818

11. Marić A, Kruljac I, Čerina V, Pećina HI, Šulentić P, Vrkljan M. Endocrinological outcomes of pure endoscopic transsphenoidal surgery: a Croatian Referral Pituitary Center experience. Croat Med J. 2012;53(3):224–233. https://doi.org/10.3325/cmj.2012-53.224

12. Berker M, Hazer DB, Yücel T, Gürlek A, Cila A, Aldur M, et al. Complications of endoscopic surgery of the pituitary adenomas: analysis of 570 patients and review of the literature. Pituitary. 2012;15(3):288–300. https://doi.org/10.1007/s11102-011-0368-2

13. Helene H, Ramm-Pettersen J, Josefsen R, Rønning P, Reilie S, Meling T, et al. Surgical complications after transsphenoidal microscopic and endoscopic surgery for pituitary adenoma: a consecutive series of 506 procedures. Acta Neurochir. 2014;156(3):441–449. https://doi.org/10.1007/s00701-013-1959-7

14. Karppinen A. 2015. Outcome after transsphenoidal surgery for pituitary adenomas—the 2000–2010 Helsinki University Hospital cohort. Helsinki: Faculty of Medicine of the University of Helsinki. http://urn.fi/URN:ISBN:978-951-51-1548-5

15. Minniti G, Jaffrain-Rea M-L, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer. 2003;10(4):611–619. https://doi.org/10.1677/erc.0.0100611

16. Rizk A, Honegger J, Milian M, Psaras T. 2012. Treatment options in Cushing’s disease. Clin Med Insights Oncol. 2012;6:75–84. https://doi.org/10.4137/CMO.S6198

17. Jane JA, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96(9):2732–2740. https://doi.org/10.1210/jc.2011-0554

18. Powell M. 1995. Recovery of vision following transsphenoidal surgery for pituitary adenomas. Br J Neurosurg. 1995;9(3):367–373. https://doi.org/10.1080/0268869950041377

19. Abtin T, Vijay KA, Yolanda B, David HH, Seth MB, Kacker A, et al. Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg. 2009;111:545–554. https://doi.org/10.3171/2007.12.17635